Crossmark

EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches

Crossref DOI link: https://doi.org/10.1186/S13046-015-0191-0

Published: 2015-12

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

Authors

D’Angelo, V.

Iannotta, A.

Ramaglia, M.

Lombardi, A.

Zarone, M. R.

Desiderio, V.

Affinita, M. C.

Pecoraro, G.

Di Martino, M.

Indolfi, P.

Casale, F.

Caraglia, M.
Funding

Funding for this research was provided by:

Regione Campania Laboratori Pubblici Progetto Hauteville (Grant code:ID0E3RAE688)

AIL (Italian Association Leukemia) (Grant code:ID0ETUAE689)

AGOP (Pediatric Oncology Association Parents) (Grant code:ID0E2VAE690)
License Information

unspecified valid from 2015-08-14